Abpro (ABP)

$0.32

-0.02 -5.88%
1D 5D 1M YTD 1Y MAX
3,000 2,500 2,000 1,500 1,000 500
January February March April May June

Stock Quote

Previous Close $0.34
Price $0.32
EPS (TTM) —
Open $0.34
% Change -5.88%
Market Cap (millions) $9.086
Volume 7,352
Volume 2,485
Beta (5Y Monthly) +1.25
Intraday High $0.32
Today's Open $0.30
Holdings Ratio —
52 Week High $4.05
52 Week High $4.05
52 Week Low —
All exchange data delayed at least 15 min, market data powered by

About Abpro

Abpro Corporation is a biotechnology company located in Woburn, Massachusetts. The company's mission is to improve the lives of patients battling cancer and life-threatening diseases with next-generation antibody therapies. In addition to novel bispecific T-cell engaging and multispecific antibody therapies, including cancer indications, such as HER2+ cancer, for breast, gastric and colorectal cancers, non-EGFR+ skin and gastric cancer, all supported by industry partners. Abpro's antibody creation technology is powered by its proprietary DiversImmune™ platform. Abpro has partnered with Cellvie, which is a leading South Korean biotechnology company, in an exclusive collaboration to further advance ABP-150, a dual-targeted VEGF+Notch bispecific which is being developed for the treatment of HER2+ breast, gastric and pancreatic cancer.

Laboratory

Latest Press Releases

Stay informed with our latest announcements, financial disclosures, and industry insights.

Abpro and Cellvie Unveil Preclinical Data for ABP-102/CT-P72 at AACR

April 27, 2024 10 min read

WOBURN, Mass., April 27, 2024 (GLOBE NEWSWIRE) -- Abpro Corporation (NASDAQ: ABP), a leader in the field of biotechnology and a clinical-stage company dedicated to developing next-generation antibody therapies, announced today preclinical data in collaboration with Cellvie, a leading biopharmaceutical company.

Read More

Abpro Announces Oral Presentation of First Preclinical Data for ABP

March 21, 2024 10 min read

ABP-100 is PT-CITE (Proprietary T-Cell Engager) built using Abpro's proprietary DiversImmune™ platform to selectively target HER2+ cancer cells. The novel immunotherapeutic platform is designed to maximize efficacy against cancerous tumors while minimizing on-target, off-tumor toxicity, compared to conventional therapies.

Read More

Abpro Statement on the Departure of Former CEO Ian Chan

Jan 29, 2024 10 min read

Announced leadership changes aimed at enhancing corporate governance and ensuring the company's innovative platform and product candidates pursue the most effective strategically important development paths through a disciplined, focused developmental approach and optimized resource allocation with excellence.

Read More

Experienced Leadership Team

Miles Suk

Miles Suk

CEO, Chairman

Robert Markiewicz, MD

Robert Markiewicz, MD

Chief Medical Officer

Governance Documents

Articles of Incorporation
Bylaws
Committee Charters
Risk Management Policy
Risk Management Policy
Code of Conduct & Ethics

SEC Filings

Stay up to date with our latest SEC filings, financial reports, and regulatory disclosures to ensure transparency and informed decision-making.

Filter Filings Type
Year
Form
Revenue ($)
Filed Date
View/Download
2024
10-Q
—
2024-05-02

Investor Email Alerts

Stay informed with the latest updates from by subscribing to our investor email alerts.